76 results
424B5
ITCI
Intra-Cellular Therapies Inc
18 Apr 24
Prospectus supplement for primary offering
5:23pm
established.
Our strategy
Our goal is to discover, develop and commercialize novel small molecule therapeutics for the treatment of CNS diseases and other … diseases which are not adequately treated by currently marketed drugs or can be effective with fewer side effects.
The key elements of our strategy
8-K
EX-99.2
ITCI
Intra-Cellular Therapies Inc
16 Apr 24
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
4:40pm
not been established.
Our strategy
Our goal is to discover, develop and commercialize novel small molecule therapeutics for the treatment of CNS … elements of our strategy are to:
continue to commercialize CAPLYTA, which has been approved by the FDA for the treatment of schizophrenia and bipolar
424B5
ITCI
Intra-Cellular Therapies Inc
16 Apr 24
Prospectus supplement for primary offering
4:37pm
and efficacy of investigational agents and/or investigational uses of approved products have not been established.
Our strategy
Our goal is to discover … by currently marketed drugs or can be effective with fewer side effects.
The key elements of our strategy are to:
continue to commercialize CAPLYTA
424B5
m9jhbp
5 Jan 22
Prospectus supplement for primary offering
4:51pm
8-K
EX-99.2
w6ydfafuy56s0
4 Jan 22
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
12:00am
424B5
itbcwc0o
3 Jan 22
Prospectus supplement for primary offering
5:30pm
8-K
EX-99.1
jfbz6pjbx 8lw2u6
9 Aug 21
Intra-cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
7:37am
PRE 14A
m1rs yglslgrday
19 Apr 21
Preliminary proxy
5:28pm